Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approvalReuters • 03/02/26
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire RetireeThe Motley Fool • 03/02/26
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains SteamZacks Investment Research • 03/02/26
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?The Motley Fool • 03/01/26
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areataPRNewsWire • 02/27/26
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The LancetPRNewsWire • 02/26/26
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.The Motley Fool • 02/25/26
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?Zacks Investment Research • 02/25/26
Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market CrashThe Motley Fool • 02/23/26